68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
ConditionNeuroendocrine Tumors (NET)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorAlberta Health services
About this trial
To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available\]
Eligibility criteria
Qualifiers
Male or female. If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required.
Age greater than or equal to 18 years.
Able and willing to follow instructions and comply with the protocol.
Provide written informed consent prior to participation in the study.
Disqualifiers
Nursing or pregnant females.
Age less than 18 years.
Surgery in the area of interest within the preceding 2 months.
Trial design
Treatments tested in this trial
- 68Ga-HA-DOTATATE PET/CT imaging
Treatment groups
500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov